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Abstract
Background: Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections.
However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially
in cases with renal dysfunction, are not well elucidated.
Case presentation: A 69-year-old Japanese woman was diagnosed as having chronic hepatitis C, genotype 1b at
the age of 55. She presented with hypertension, microscopic hematuria, proteinuria, renal dysfunction, purpura, and
arthralgia at the age of 61. She also had hypocomplementemia and cryoglobulinemia. Renal biopsy revealed
membranoproliferative glomerulonephritis (MPGN), and she was diagnosed as having HCV-associated
cryoglobulinemic MPGN. She declined interferon therapy at the time and was treated with antihypertensive
medications as well as oral corticosteroid that were effective in reducing proteinuria. However, when the
corticosteroid dose was reduced, proteinuria worsened. She began antiviral treatment with daclatasvir/asunaprevir
(DCV/ASV). Clearance of HCV-RNA was obtained by 2 weeks and sustained, and liver function was normalized. In
addition, microhematuria turned negative, proteinuria decreased, hypocomplementemia and estimated glomerular
filtration rate were improved, whereas cryoglobulinemia persisted. She completed 24 weeks of therapy without
significant adverse effects.
Conclusion: In a case of HCV-associated cryoglobulinemic MPGN with renal dysfunction, DCV/ASV -based DAAs
ameliorated microhematuria, proteinuria and renal function without significant side effects.
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Background
Recently, several direct-acting antivirals (DAAs) have
been approved for treating hepatitis C virus (HCV)
infections. The emergence of DAAs dramatically
changed HCV treatments with superior rates of sus-
tained viral response (SVR) and fewer side effects
than the conventional interferon-based therapy. Infor-
mation about the effects of DAAs on extra-hepatic
manifestations, such as HCV-associated glomerulo-
nephritis, skin lesions and neuropathy, is limited. Sise
et al. reported that sofosbuvir-based DAAs therapy
reduced proteinuria and increased estimated glomeru-
lar filtration rate (eGFR) in 3 of 7 patients with
HCV-associated glomerulonephritis [1], although,
sofosbuvir is contraindicated in patients with an eGFR
of less than 30 ml/min/1.73 m2 Saadoun et al. re-
ported that sofosbuvir plus ribavirin were effective in
4 of 5 patients with HCV-associated glomeruloneph-
ritis [2], although ribavirin is generally contraindicated
in patients with a creatinine clearance of less than
50 mL/min. Thus information on the efficacy and
safety in patients with impaired renal function is lim-
ited. Daclatasvir (DCV) is a NS5A replication com-
plex inhibitor, and asunaprevir (ASV) is a selective
NS3 protease inhibitor [3]. Both DCV and ASV have
demonstrated robust antiviral activity against HCV [3, 4],
and the combination of DCV and ASV as all-oral therapy
was approved in Japan for the treatment of HCV hepatitis
genotype 1b. This is an important option, especially for
patients with renal impairments, since both DCV and
ASV have minimal renal excretion and no dosage adjust-
ment of DCV and ASV is generally required for patients
with any degree of impaired renal function.
We demonstrate that novel DAA therapy with DCV/
ASV improved renal function, microhematuria and pro-
teinuria in a case of HCV-associated cryoglobulinemic
membranoproliferative glomerulonephritis (MPGN).
Case presentation
A 55-year-old Japanese woman, with no prior history
of blood transfusion, drug addiction, or having tattoos
was diagnosed as having an HCV infection at the
local clinic where she had been treated for hyperten-
sion. At the age of 61, she complained of exanthems
in both her lower extremities and arthralgia in her
knees. She had purpura, and skin biopsy revealed leu-
kocytoclastic angitis. Then, she was referred to a
nephrologist since she had microscopic hematuria,
proteinuria and renal dysfunction. At the time of re-
ferral, her blood pressure was 127/80 mmHg, her
hight was 144.5 cm and her weight was 63.0 kg. She
exhibited edema in her face and both lower extrem-
ities. Fresh purpura was present on her legs. Labora-
tory values at the time of referral were as follows:
white blood cells 4470/μL, hemoglobin 11.4 g/dL,
platelets 194 × 103 μL, hepaplastin test 120%, total
protein 7.2 g/dL, albumin 4.2 g/dL, cholinesterase 280
U/l, lactate dehydrogenase 155 U/L, glutamate oxalo-
acetate transaminase 33 U/ml, glutamate pyruvate
transaminase 32 U/L, γ-glutamyl trans peptidase 40U/
L, blood urea nitrogen 21 mg/dL, creatinine 1.2 mg/
dL, eGFR 36.1 ml/min/1.73 m2, C-reactive protein
0.2 mg/dL, MPO-ANCA <10 EU, PR3-ANCA <10
EU, anti nuclear antibody × 40 (normal limit < ×40),
rheumatoid factor 436 (0–15) IU/ml, IgG 1752
(1100–1700) mg/dl, IgA 169 (110–410) mg/dl, IgM
228 (46–260) mg/dl, C3 51 (65–135) mg/dl, C4 3
(13–35) mg/dl, CH50 < 10 (23–46) U/ml and cryoglobu-
lin was positive. Urinalysis showed hematuria (+++): sedi-
ment red blood cells >100/high power field (HPF) and
proteinuria 0.78 g/day.
A renal biopsy was performed. On light microscopy,
30 glomeruli were observed and 4 glomeruli exhibited
global sclerosis. Many other glomeruli exhibited mesan-
gial hypercellularity, lobular accentuation and double
contour of basement membrane (Fig. 1a). Pseudothrimbi
and tubuloreticular inclusions were not observed. Im-
munofluorescent analysis showed a positive fringe pat-
tern for IgG, IgM (Fig. 1b), C3. Staining for IgA was
negative. Electron microscopy was not performed.
Therefore, her case was diagnosed as having MPGN.
Since, she was HCV positive, and had hypocomplemen-
temia and cryoglobulinemia, she was diagnosed as hav-
ing HCV-related cryoglobulinemic MPGN.
She was then referred to a hepatologist. Liver biopsy
revealed chronic hepatitis and there were no signs of cir-
rhosis. She was diagnosed with chronic hepatitis due to
HCV. At the time, she declined interferon therapy be-
cause she was regularly seeing a psychiatrist and taking
anti-anxiety medication and was concerned about de-
pression as a side effect. She was treated with antihyper-
tensive medications, including renin-angiotensin system
blockers as well as oral corticosteroid which were effect-
ive in reducing proteinuria. However, proteinuria was
exacerbated following the reduction of corticosteroid
and often reached nephrotic levels. She began anti-viral
therapy using DAAs. Because of renal dysfunction, DCV
and ASV were selected. Variation in Y93/L31, which is
related to DCV resistance, was negative. DCV (60 mg/
day) and ASV (200 mg/day) were initiated. Clearance of
HCV RNA was obtained by 2 weeks and sustained, and
liver function was normalized. In addition, microhema-
turia turned negative, proteinuria decreased, hypocom-
plementemia and eGFR improved, whereas
cryoglobulinemia persisted. Arthralgia and purpura were
not active during the treatment. Data are summarized in
Table 1. She completed 24 weeks of therapy without sig-
nificant adverse effects.
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Discussion
To our knowledge, this is the first case report which
demonstrates renoprotective effects of novel DAAs ther-
apy with DCV/ASV in the case of biopsy proven HCV-
related cryoglobulinemic MPGN. This was a case of
HCV chronic hepatitis with concomitant MPGN, arth-
ralgia and purpura due to cryoglobulinemia. Multi-drug
antihypertensive therapy including renin-angiotensin
system blockade and oral corticosteroid therapy had
been used but proteinuria was persistent and she had
chronic kidney disease stage 3B renal impairment. Then
DCV/ASV-based DAA therapy was employed, and a
prompt antiviral response, normalization of liver func-
tion and subsequent improvement of eGFR, hypocom-
plementemia, hematuria and proteinuria were obtained
without significant side effects. In contrast, cryoglobuli-
nemia was persistent. However, this is consistent with a
previous report showing that cryoglobulinemia persisted
even after the clearance of HCV virus [5].
HCV infection leads to chronic liver disease, as well as
extra-hepatic manifestations which usually derive from
HCV-associated cryoglobulinemic vasculitis. The relation-
ship between HCV and MPGN was initially described in
1993 [6]. At present, it is known that MPGN accompanied
with cryoglobulinemia is the most common form of HCV-
related glomerulonephropathy [7], and it is often accom-
panied with hypocomplementemia, rheumatoid factor and
cryoglobulinemia [5]. Interferon therapy was effective in
reducing proteinuria [8]; however, its effect was limited
and dependent on the achievement of SVR [9], and recur-
rence of proteinuria was very common with the recurrence
of viremia [10]. Therefore, proteinuria was often persistent
and renal insufficiency was progressive. Combined antiviral
therapy using pegylated interferon and ribavirin
Table 1 Laboratory data during DCV/ASV therapy
Data Normal range
Weeks 0 4 10 14 18 22 24
Creatinine (0.4–0.7) 1.83 1.51 1.33 1.07 1.18 1.1 1.06
eGFR (mL/min/1.73 m2) 25.9 27.2 31.1 39.5 35.5 35.5 38.3
C3 (mg/dl) (35–65) 56 86 87 96 95 99 94
C4 (mg/dl) (13–35) 1 4 3 4 3 3 3
CH50 (U/mL) (23–46) 10 17.2 17.4 39.6 31.9 32.7 29.1
Proteinuria (g/g cre) (<0.15) 1.94 0.62 0.16 1.38 0.65 0.93 0.13
Hematuria(/HPF) (<5) 50 10.8 5.3 15.3 10.8 12.2 3.9
Cryoglobulin (−) + + + +
GOT (U/L) (13–33) 32 27 25 24 24 27 24
GPT (U/L) (6–27) 32 23 23 22 21 19 20
γ-GTP (U/L) (10–47) 63 51 32 26 24 24 22
Abbreviations: eGFR estimated glomerular filtration rate, HPF high power field, GOT glutamate oxaloacetate transaminase, GPT glutamate pyruvate transaminase, γ-
GTP γ-glutamyl trans peptidase
Fig. 1 a Light microscopy findings of kidney biopsy. Periodic acid-Schiff stain reveals mesangial hypercellularity, lobular accentuation and double
contour of the basement membrane. (original magnification, ×400). b. Immunofluorescent staining of IgM was positive along the capillary loop.
(original magnification, ×400)
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significantly improved treatment outcome. However, riba-
virin is contraindicated if eGFR is less than 50 mL/min/
1.73 m2, and the patients who were not able to obtain SVR
usually did not receive the benefit. Treatment guidelines
suggest that patients with HCV and mixed cryoglobuline-
mia with nephrotic proteinuria, or evidence of progressive
kidney disease, or an acute flare of cryoglobulinemia, will
benefit from treatment with plasmapheresis, rituximab, or
cyclophosphamide, in conjunction with intravenous meth-
ylprednisolone, and concomitant antiviral therapy [11, 12].
Rituximab contributed to improved renal outcome, how-
ever, the effects were often transient and repeated treat-
ment was required [13, 14].
Recent induction of DAA therapy has dramatically
changed HCV treatment, with superior rates of SVR and
fewer side effects. Therefore, improvements in HCV-
associated glomerulonephritis are also expected. How-
ever, we are awaiting further evidences showing efficacy
and safety in patients with impaired renal function.
Tsuge et al. reported a case of improved eGFR with
DCV/ASV therapy in a case of HCV cirrhosis, however,
renal histology in this case is not available [15].
Conclusion
DCV/ASV-based DAA therapy ameliorated microhema-
turia, proteinuria and renal function in a case of HCV-
related cryoglobulinemic MPGN with renal dysfunction.
Since this is a case report, further evidence for the efficacy
and safety in patients with renal impairments is needed.
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